Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes
Φόρτωση...
Ημερομηνία
Συγγραφείς
Papathanassiou, K.
Naka, K. K.
Kazakos, N.
Kanioglou, C.
Makriyiannis, D.
Pappas, K.
Katsouras, C. S.
Liveris, K.
Kolettis, T.
Tsatsoulis, A.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Atherosclerosis
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
OBJECTIVE: The aim of this study was to compare the effect of glimepiride and pioglitazone on endothelial function in patients with type 2 diabetes already on metformin. METHODS: Twenty-eight patients with type 2 diabetes already on metformin, without known cardiovascular disease, were randomized in 2 groups; glimepiride (4 mg od) was added in group A (n=14) and pioglitazone (30 mg od) in group B (n=14) for 6 months. Flow-mediated dilation (FMD) in the brachial artery was assessed in all patients, at baseline and at follow-up. RESULTS: The 2 groups did not differ in age (mean+/-S.D., 63.6+/-7.3 years vs 62.8+/-7.2 years respectively), or any measured variable at baseline. Fasting glucose and glycated haemoglobin improved similarly in both groups. There were significant differences between the 2 groups in the absolute changes observed at follow-up in waist circumference, +1.86+/-3.11 cm vs -1.86+/-1.88 cm in groups A and B respectively; fasting insulin levels, +14.79+/-12.56 pmol/L vs -25.84+/-28.09 pmol/L; homeostasis model assessment (HOMA), +0.66+/-1.01 vs -1.83+/-1.38; HDL cholesterol levels, -0.07+/-0.22 mmol/L vs +0.14+/-0.20 mmol/L and FMD, +0.14+/-1.09% vs +2.02+/-2.05% (p<0.05 for all). The only independent predictor factor of the FMD improvement was treatment-induced changes in HOMA (R(2): 0.488, slope: -0.782, [95% CI: -1.128, -0.436], p=0.0001). CONCLUSIONS: In patients with type 2 diabetes already on metformin, addition of pioglitazone as compared to glimepiride, improved endothelial function despite similar glycemic control. The improvement in endothelial function was mainly due to a reduction in insulin resistance.
Περιγραφή
Λέξεις-κλειδιά
Aged, Blood Glucose/metabolism, Diabetes Mellitus, Type 2/*drug therapy, Endothelium, Vascular/*drug effects, Female, Humans, Hypoglycemic Agents/therapeutic use, Insulin Resistance, Male, Metformin/therapeutic use, Middle Aged, Sulfonylurea Compounds/*therapeutic use, Thiazolidinediones/*therapeutic use, Treatment Outcome
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/19135671
http://ac.els-cdn.com/S0021915008008411/1-s2.0-S0021915008008411-main.pdf?_tid=432e7f32fe766702610c0511a746e1ae&acdnat=1333969737_a0ef08da311b591d5bd9216ef71f05cf
http://ac.els-cdn.com/S0021915008008411/1-s2.0-S0021915008008411-main.pdf?_tid=432e7f32fe766702610c0511a746e1ae&acdnat=1333969737_a0ef08da311b591d5bd9216ef71f05cf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής